The PCAST Report: Impact and Implications for the Pharmaceutical Industry

被引：10
|
作者：
Morris, S. A. [1 ]
Rosenblatt, M. [2 ]
Orloff, J. J. [3 ]
Lewis-Hall, F. [4 ]
Waldstreicher, J. [1 ]
机构：
[1] Johnson & Johnson, New Brunswick, NJ USA
[2] Merck & Co Inc, Whitehouse Stn, NJ USA
[3] Novartis Pharmaceut, E Hanover, NJ USA
[4] Pfizer Inc, New York, NY USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2013年 / 94卷 / 03期
关键词：
D O I：
10.1038/clpt.2013.93
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The President's Council of Advisors on Science and Technology (PCAST) report sets out an ambitious goal: to double the output of innovative, new medicines with increased efficacy and safety within the next 10-15 years. If attainable, this could change the face of medicine and bring great benefit to society. Clear leadership, commitment to action, and unprecedented collaboration will be essential if the goal of the report is to be realized.
引用
收藏
页码：300 / 302
页数：3
相关论文
共 50 条
12345